APIM Therapeutics AS Raises €440,000

APIM Therapeutics AS, a spin-out from The Norwegian University of Science and Technology (NTNU), has raised NOK3.5m (approximately €440.000) from Sarsia Seed AS.
The company has developed novel peptide drugs, which have the potential to improve clinical outcomes achieved with a large group of existing first line chemotherapeutics.
Sarsia Seed is a Seed Capital Fund which invests in Norway-based early phase technology companies within the energy, cleantech and biotechnology/life science sectors.

Join the discussion